Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus platinum–etoposide in untreated extensive-stage small cell lung cancer
2019-002784-10Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of atezolizumab in small cell lung cancer (SCLC), sponsored by Roche. Primary endpoint: Safety profile of atezolizumab + platinum–etoposide. Started Oct 2019; status: completed.
02
Drugs
atezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2019-002784-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002784-10.